Guillaume Louis
Guillaume Louis is an expert in Critical care at Centre Hospitalier Régional de Metz-Thionville (France). As of October 2026, ScienceLeadR ranks Guillaume Louis in the top 1% of experts worldwide for Pneumonia, Coronavirus Infections and COVID-19. Guillaume Louis has authored 118 publications, the most recent in 2026, and is an investigator in 33 clinical trials, 9 of them ongoing. SLR score: 717 (community average: 125). How the SLR is computed.
LeadR Profile
Critical care
Subspecialties: Infectiology - Public Health - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2026
Number : 118
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Determinants of neurologic causes and systemic causes of death in severe meningitis and encephalitis: insights from the international prospective multicenter EURECA study. PMID 42776196 — cause of death, critical care, meningitis, intensive care units, encephalitis | Intensive Care Med | 2026 | 0 |
| AKI in Severe Legionnaires' Disease in Intensive Care Unit. PMID 42751414 — proteinuria, mortality, incidence, legionella, kidney, legionnaires' disease, therapeutics, intensive care units, rhabdomyolysis, prognosis | Kidney Int Rep | 2026 | 0 |
| Unclassifiable Invasive Pulmonary Aspergillosis in the Intensive Care Unit: Insights From a Multicenter, Retrospective Cohort Study in France (2022-2024). PMID 42682890 — mortality, cohort studies, pulmonary aspergillosis, invasive pulmonary aspergillosis, mycoses, cluster analysis, therapeutics, intensive care units, frailty, aspergillosis | Open Forum Infect Dis | 2026 | 0 |
| Complement augments antibody neutralization of SARS-CoV-2 variants. PMID 42485435 — sars-cov-2, virion, antibodies, viruses, immunity, complement system proteins, severe acute respiratory syndrome-related coronavirus | Sci Transl Med | 2026 | 0 |
| Acute kidney injury in immunocompromised patients with acute respiratory failure: insights from the HIGH clinical trial and relation with mechanical ventilation. PMID 41859565 — kidney, immunocompromised host, ventilation, acute kidney injury | Ann Intensive Care | 2026 | 0 |
Clinical Studies 33
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 19
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Early Corticosteroids in Severe Influenza Pneumonia NCT07786662 — injections, hygiene, dexamethasone, adrenal cortex hormones, pneumonia, influenza, human, therapeutics, intensive care units, respiratory distress syndrome, random allocation, communicable diseases, injections, intravenous | Phase 3 | Not yet recruiting | 2026 |
| DASSOH Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia a multicenter open label randomized controlled trial 2023-507254-32-00 — serum, hyponatremia | Phase 3 | Recruiting | 2024 |
| Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock and or acute respiratory failure an open multicentric randomized phase IV study 2024-518493-14-00 — shock, septic, kidney, transplants, intensive care units, kidney transplantation, immunosuppression therapy, transplantation | Phase 2/Phase 3 | Recruiting | 2026 |
| Use of MULTIplex PCR procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation a trial controlled randomized open in parallel groups multicenter 2024-511896-13-00 — procalcitonin, polymerase chain reaction, multiple chronic conditions, multiplex polymerase chain reaction, pulmonary disease, chronic obstructive, sputum, therapeutics, ventilation | Phase 3/Phase 4 | Recruiting | 2022 |
| Prophylactic ANTicoagulation With HEparine in Critically Ill Patients With Renal Impairment NCT07365644 — heparin, critical illness, risk factors, intensive care units, thrombosis, renal insufficiency | N/A | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map